Pulmatrix (NASDAQ:PULM) Stock Crosses Above Fifty Day Moving Average – What’s Next?

Shares of Pulmatrix, Inc. (NASDAQ:PULM) crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.58 and traded as high as $1.72. Pulmatrix shares last traded at $1.66, with a volume of 17,326 shares traded.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Pulmatrix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Pulmatrix Stock Performance

The firm’s 50-day moving average price is $1.58 and its two-hundred day moving average price is $1.81. The firm has a market cap of $6.06 million, a PE ratio of -1.35 and a beta of 1.91.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Friday, May 15th. The biotechnology company reported ($0.32) EPS for the quarter.

Institutional Trading of Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP bought a new stake in Pulmatrix, Inc. (NASDAQ:PULM) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned about 0.30% of Pulmatrix as of its most recent filing with the Securities and Exchange Commission. 11.84% of the stock is currently owned by hedge funds and other institutional investors.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).